JNK signaling provides a novel therapeutic target for Rett syndrome.
Apnea
D-JNKI1
MECP2
Neurodevelopmental disease
Neuroprotection
Synaptic dysfunction
Journal
BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720
Informations de publication
Date de publication:
16 12 2021
16 12 2021
Historique:
received:
01
06
2021
accepted:
11
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
3
2022
Statut:
epublish
Résumé
Rett syndrome (RTT) is a monogenic X-linked neurodevelopmental disorder characterized by loss-of-function mutations in the MECP2 gene, which lead to structural and functional changes in synapse communication, and impairments of neural activity at the basis of cognitive deficits that progress from an early age. While the restoration of MECP2 in animal models has been shown to rescue some RTT symptoms, gene therapy intervention presents potential side effects, and with gene- and RNA-editing approaches still far from clinical application, strategies focusing on signaling pathways downstream of MeCP2 may provide alternatives for the development of more effective therapies in vivo. Here, we investigate the role of the c-Jun N-terminal kinase (JNK) stress pathway in the pathogenesis of RTT using different animal and cell models and evaluate JNK inhibition as a potential therapeutic approach. We discovered that the c-Jun N-terminal kinase (JNK) stress pathway is activated in Mecp2-knockout, Mecp2-heterozygous mice, and in human MECP2-mutated iPSC neurons. The specific JNK inhibitor, D-JNKI1, promotes recovery of body weight and locomotor impairments in two mouse models of RTT and rescues their dendritic spine alterations. Mecp2-knockout presents intermittent crises of apnea/hypopnea, one of the most invalidating RTT pathological symptoms, and D-JNKI1 powerfully reduces this breathing dysfunction. Importantly, we discovered that also neurons derived from hiPSC-MECP2 mut show JNK activation, high-phosphorylated c-Jun levels, and cell death, which is not observed in the isogenic control wt allele hiPSCs. Treatment with D-JNKI1 inhibits neuronal death induced by MECP2 mutation in hiPSCs mut neurons. As a summary, we found altered JNK signaling in models of RTT and suggest that D-JNKI1 treatment prevents clinical symptoms, with coherent results at the cellular, molecular, and functional levels. This is the first proof of concept that JNK plays a key role in RTT and its specific inhibition offers a new and potential therapeutic tool to tackle RTT.
Sections du résumé
BACKGROUND
Rett syndrome (RTT) is a monogenic X-linked neurodevelopmental disorder characterized by loss-of-function mutations in the MECP2 gene, which lead to structural and functional changes in synapse communication, and impairments of neural activity at the basis of cognitive deficits that progress from an early age. While the restoration of MECP2 in animal models has been shown to rescue some RTT symptoms, gene therapy intervention presents potential side effects, and with gene- and RNA-editing approaches still far from clinical application, strategies focusing on signaling pathways downstream of MeCP2 may provide alternatives for the development of more effective therapies in vivo. Here, we investigate the role of the c-Jun N-terminal kinase (JNK) stress pathway in the pathogenesis of RTT using different animal and cell models and evaluate JNK inhibition as a potential therapeutic approach.
RESULTS
We discovered that the c-Jun N-terminal kinase (JNK) stress pathway is activated in Mecp2-knockout, Mecp2-heterozygous mice, and in human MECP2-mutated iPSC neurons. The specific JNK inhibitor, D-JNKI1, promotes recovery of body weight and locomotor impairments in two mouse models of RTT and rescues their dendritic spine alterations. Mecp2-knockout presents intermittent crises of apnea/hypopnea, one of the most invalidating RTT pathological symptoms, and D-JNKI1 powerfully reduces this breathing dysfunction. Importantly, we discovered that also neurons derived from hiPSC-MECP2 mut show JNK activation, high-phosphorylated c-Jun levels, and cell death, which is not observed in the isogenic control wt allele hiPSCs. Treatment with D-JNKI1 inhibits neuronal death induced by MECP2 mutation in hiPSCs mut neurons.
CONCLUSIONS
As a summary, we found altered JNK signaling in models of RTT and suggest that D-JNKI1 treatment prevents clinical symptoms, with coherent results at the cellular, molecular, and functional levels. This is the first proof of concept that JNK plays a key role in RTT and its specific inhibition offers a new and potential therapeutic tool to tackle RTT.
Identifiants
pubmed: 34911542
doi: 10.1186/s12915-021-01190-2
pii: 10.1186/s12915-021-01190-2
pmc: PMC8675514
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
256Informations de copyright
© 2021. The Author(s).
Références
Eur J Hum Genet. 2015 Feb;23(2):195-201
pubmed: 24916645
J Clin Neurosci. 2014 May;21(5):810-4
pubmed: 24405770
Brain Pathol. 2007 Oct;17(4):448-59
pubmed: 17919130
Front Biosci (Landmark Ed). 2017 Jan 1;22:795-814
pubmed: 27814647
Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):63-7
pubmed: 15723614
Acta Paediatr. 2001 Jan;90(1):34-9
pubmed: 11227330
J Am Assoc Lab Anim Sci. 2012 May;51(3):352-6
pubmed: 22776194
Biochim Biophys Acta. 2013 Jun;1833(6):1476-88
pubmed: 23485395
Diabetes. 2001 Jan;50(1):77-82
pubmed: 11147798
Exp Biol Med (Maywood). 2011 Jan;236(1):3-19
pubmed: 21239731
Hum Mol Genet. 2011 Mar 15;20(6):1182-96
pubmed: 21212100
Int J Mol Med. 2017 Dec;40(6):1615-1623
pubmed: 29039455
Otol Neurotol. 2019 Jun;40(5):584-594
pubmed: 31083077
Brain Res. 1999 Jul 17;835(1):18-26
pubmed: 10448192
J Child Neurol. 1988;3 Suppl:S6-16
pubmed: 3058788
Cells. 2020 Jul 29;9(8):
pubmed: 32751228
Cell Signal. 2001 May;13(5):299-310
pubmed: 11369511
J Alzheimers Dis. 2011;26(2):315-29
pubmed: 21628793
J Physiol. 2007 Mar 15;579(Pt 3):863-76
pubmed: 17204503
J Comp Neurol. 2009 May 20;514(3):240-58
pubmed: 19296534
Psychol Bull. 1976 May;83(3):482-504
pubmed: 17582919
Pharmaceuticals (Basel). 2010 Feb 03;3(2):379-392
pubmed: 27713257
Respir Physiol Neurobiol. 2008 Dec 10;164(1-2):55-63
pubmed: 18534925
Front Mol Neurosci. 2018 Sep 04;11:308
pubmed: 30233310
Ment Retard Dev Disabil Res Rev. 2002;8(2):87-93
pubmed: 12112733
Pediatr Res. 2006 Oct;60(4):443-9
pubmed: 16940240
Drug Metab Dispos. 2008 Feb;36(2):375-9
pubmed: 18006649
eNeuro. 2018 Sep 24;5(5):
pubmed: 30255129
J Biol Chem. 2011 Dec 23;286(51):43871-43880
pubmed: 22033930
Front Psychiatry. 2012 May 08;3:34
pubmed: 22586411
Pediatr Neurol. 2015 Nov;53(5):402-11
pubmed: 26278631
Neurobiol Dis. 2020 Jul;140:104812
pubmed: 32087286
Nat Neurosci. 2011 Mar;14(3):285-93
pubmed: 21346746
Pediatr Neurol. 2018 Mar;80:88-89
pubmed: 29373156
J Neuropathol Exp Neurol. 2005 Jun;64(6):537-44
pubmed: 15977646
Neuron. 2007 Nov 8;56(3):422-37
pubmed: 17988628
Curr Opin Neurobiol. 2009 Apr;19(2):231-4
pubmed: 19545994
Neuroscience. 2018 Nov 21;393:196-205
pubmed: 30315879
Front Biol (Beijing). 2012 Oct;7(5):428-435
pubmed: 24999353
J Neurosci. 2005 Dec 14;25(50):11521-30
pubmed: 16354910
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12560-5
pubmed: 16116096
Nat Rev Neurosci. 2014 May;15(5):285-99
pubmed: 24739785
Nat Genet. 1999 Oct;23(2):185-8
pubmed: 10508514
Respir Physiol Neurobiol. 2009 Aug 31;168(1-2):101-8
pubmed: 19394452
Nat Commun. 2016 Jan 29;7:10520
pubmed: 26821816
J Psychiatry Neurosci. 2019 Nov 08;45(3):150-181
pubmed: 31702122
Ment Retard Dev Disabil Res Rev. 2002;8(2):61-5
pubmed: 12112728
Neuron. 2007 Nov 8;56(3):488-502
pubmed: 17988632
Oncotarget. 2017 Aug 3;8(47):83038-83051
pubmed: 29137322
Epigenetics. 2007 Apr-Jun;2(2):126-34
pubmed: 17965627
J Vis Exp. 2015 Feb 06;(96):e52434
pubmed: 25742564
Elife. 2016 Jun 21;5:
pubmed: 27328321
Science. 2011 Jul 8;333(6039):186
pubmed: 21636743
Future Med Chem. 2015;7(15):2065-86
pubmed: 26505831
Prog Brain Res. 2012;197:153-68
pubmed: 22541292
Am J Alzheimers Dis Other Demen. 2002 Mar-Apr;17(2):79-88
pubmed: 11954673
Exp Neurol. 2009 Jan;215(1):191-200
pubmed: 19022249
Nat Med. 2003 Sep;9(9):1180-6
pubmed: 12937412
Science. 2007 Feb 23;315(5815):1143-7
pubmed: 17289941
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Nat Protoc. 2009;4(12):1828-44
pubmed: 20010937
Neurosci Biobehav Rev. 2019 Dec;107:115-135
pubmed: 31108160
Cell Rep. 2018 May 8;23(6):1665-1677
pubmed: 29742424
Cell Death Dis. 2015 Aug 13;6:e1854
pubmed: 26270349
J Mol Cell Biol. 2013 Aug;5(4):277-9
pubmed: 23606726
Brain Res Brain Res Rev. 2002 Jun;39(1):29-54
pubmed: 12086707
Eur J Hum Genet. 2011 Dec;19(12):1246-55
pubmed: 21750574
Oncogene. 2008 Oct 20;27(48):6245-51
pubmed: 18931691
Neurobiol Dis. 2016 May;89:101-11
pubmed: 26721320
Exp Cell Res. 2018 Jul 15;368(2):225-235
pubmed: 29730163
Neurol Clin. 2002 Nov;20(4):1125-41
pubmed: 12616684
Cell. 1992 Jun 12;69(6):905-14
pubmed: 1606614
Neurobiol Dis. 2009 Mar;33(3):518-25
pubmed: 19166938
J Neurodev Disord. 2009 Sep;1(3):185-96
pubmed: 19966931
Mol Biosyst. 2016 Jul 19;12(8):2532-40
pubmed: 27263470
J Neurosci. 2001 Mar 1;21(5):1501-9
pubmed: 11222640
Cell Death Dis. 2014 Jan 23;5:e1019
pubmed: 24457963
J Neuroinflammation. 2012 Jul 17;9:175
pubmed: 22805152
EMBO J. 2008 Jan 23;27(2):361-72
pubmed: 18188153
J Neurosci. 2013 Aug 21;33(34):13612-20
pubmed: 23966684
Drug News Perspect. 2004 Dec;17(10):646-54
pubmed: 15696229
J Anat. 2010 Oct;217(4):324-33
pubmed: 20408906
Trends Neurosci. 2016 Feb;39(2):100-113
pubmed: 26830113
Nature. 1997 Oct 23;389(6653):865-70
pubmed: 9349820
Elife. 2016 Jun 21;5:
pubmed: 27328325
Neuropharmacology. 2014 Jan;76 Pt C:737-46
pubmed: 23597512
Respir Physiol Neurobiol. 2013 Nov 1;189(2):280-7
pubmed: 23816600
Front Neurosci. 2018 Jun 19;12:412
pubmed: 29970983